(Q30426863)

21 June 2017

1 reference

title

Nontuberculous mycobacterial infections (English)

1 reference

21 June 2017

French AL

1

1 reference

PubMed ID

9093233

21 June 2017

Benator DA

series ordinal

2

1 reference

PubMed ID

9093233

21 June 2017

Gordin FM

series ordinal

3

1 reference

21 June 2017

1 March 1997

1 reference

Medical Clinics of North America

21 June 2017

1 reference

21 June 2017

81

1 reference

21 June 2017

2

1 reference

21 June 2017

361-379

1 reference

Mycobacterium xenopi Infections in the Acquired Immunodeficiency Syndrome

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium kansasii among patients infected with human immunodeficiency virus in Kansas City. Kansas City AIDS Research Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium gordonae: a possible opportunistic respiratory tract pathogen in patients with advanced human immunodeficiency virus, type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium avium complex infection and AIDS: advances in theory and practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Central nervous system infection with Mycobacterium kansasii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

An Animal Model of Mycobacterium avium Complex Disseminated Infection after Colonization of the Intestinal Tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Progressive disseminated infection with Mycobacterium avium complex after intravenous and oral challenge in cyclosporine-treated rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium celatum sp. nov

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium gordonae in the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium kansasii presenting as an endobronchial lesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium ulcerans associated with infection due to the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Varied Presentations and Responses to Treatment of Infections Caused by Mycobacterium haemophilum in Patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium chelonae infection of lymph nodes in an HIV-infected patient.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium xenopi infection in a patient with acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium kansasii septic arthritis in a patient with acquired immune deficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium avium-intracellulare: A Cause of Disseminated Life-Threatening Infection in Homosexuals and Drug Abusers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium avium and Mycobacterium intracellulare infections in patients with and without AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Uveitis associated with rifabutin prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium avium strains resistant to clarithromycin and azithromycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Environmental risk factors for acquisition of Mycobacterium avium complex in persons with human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium simiae infection in Israeli patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Nontuberculous mycobacterial infection of the central nervous system in patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Natural History of Disseminated Mycobacterium avium Complex Infection in AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: Disease-Specific Recommendations*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium kansasii: A Cause of Treatable Pulmonary Disease Associated with Advanced Human Immunodeficiency Virus (HIV) Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium kansasii sinusitis in a patient with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium kansasii pericarditis in patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Absence of bacteremia with Mycobacterium avium-intracellulare in Ugandan patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Clinical and epidemiologic features of infection with Mycobacterium genavense. Swiss HIV Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Disseminated Mycobacterium scrofulaceum infection: a potentially treatable complication of AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Rifampin-resistant Mycobacterium kansasii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Clinical Manifestations and Implications of Coinfection with Mycobacterium kansasii and Human Immunodeficiency Virus Type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Disease due to the Mycobacterium avium complex in patients infected with human immunodeficiency virus: diagnosis and susceptibility testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

High predictive value of the acid-fast smear for Mycobacterium tuberculosis despite the high prevalence of Mycobacterium avium complex in respiratory specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

Extrapulmonary and disseminated infections due to Mycobacterium malmoense: case report and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Comparison of three methods for recovery of Mycobacterium avium complex from blood specimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970522-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(05)70522-8

1 reference

21 June 2017

1 reference

PubMed ID

9093233